159 related articles for article (PubMed ID: 17055272)
21. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
[TBL] [Abstract][Full Text] [Related]
23. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.
Nordhoff S; López-Canet M; Hoffmann-Enger B; Bulat S; Cerezo-Gálvez S; Hill O; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4818-23. PubMed ID: 19576767
[TBL] [Abstract][Full Text] [Related]
24. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Wiedeman PE; Trevillyan JM
Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
[TBL] [Abstract][Full Text] [Related]
26. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
29. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797
[TBL] [Abstract][Full Text] [Related]
30. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
31. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
[TBL] [Abstract][Full Text] [Related]
32. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
33. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
[No Abstract] [Full Text] [Related]
34. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.
Kim D; Kowalchick JE; Brockunier LL; Parmee ER; Eiermann GJ; Fisher MH; He H; Leiting B; Lyons K; Scapin G; Patel SB; Petrov A; Pryor KD; Roy RS; Wu JK; Zhang X; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2008 Feb; 51(3):589-602. PubMed ID: 18201067
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.
Ahn JH; Shin MS; Jun MA; Jung SH; Kang SK; Kim KR; Rhee SD; Kang NS; Kim SY; Sohn SK; Kim SG; Jin MS; Lee JO; Cheon HG; Kim SS
Bioorg Med Chem Lett; 2007 May; 17(9):2622-8. PubMed ID: 17331715
[TBL] [Abstract][Full Text] [Related]
39. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
